Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial

{ 'indexed': {'date-parts': [[2022, 3, 16]], 'date-time': '2022-03-16T22:05:18Z', 'timestamp': 1647468318511}, 'reference-count': 48, 'publisher': 'Springer Science and Business Media LLC', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2021, 3, 30]], 'date-time': '2021-03-30T00:00:00Z', 'timestamp': 1617062400000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}, { 'start': { 'date-parts': [[2021, 3, 30]], 'date-time': '2021-03-30T00:00:00Z', 'timestamp': 1617062400000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}], 'funder': [ { 'DOI': '10.13039/100006521', 'name': 'SU | School of Medicine, Stanford University', 'doi-asserted-by': 'publisher', 'award': ['Anonymous Donors']}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'short-container-title': ['Nat Commun'], 'published-print': {'date-parts': [[2021, 12]]}, 'abstract': '<jats:title>Abstract</jats:title><jats:p>Type III interferons have been touted as promising ' 'therapeutics in outpatients with coronavirus disease 2019 (COVID-19). We conducted a ' 'randomized, single-blind, placebo-controlled trial (NCT04331899) in 120 outpatients with mild ' 'to moderate COVID-19 to determine whether a single, 180 mcg subcutaneous dose of ' 'Peginterferon Lambda-1a (Lambda) within 72 hours of diagnosis could shorten the duration of ' 'viral shedding (primary endpoint) or symptoms (secondary endpoint). In both the 60 patients ' 'receiving Lambda and 60 receiving placebo, the median time to cessation of viral shedding was ' '7 days (hazard ratio [HR] = 0.81; 95% confidence interval [CI] 0.56 to 1.19). Symptoms ' 'resolved in 8 and 9 days in Lambda and placebo, respectively, and symptom duration did not ' 'differ significantly between groups (HR 0.94; 95% CI 0.64 to 1.39). Both Lambda and placebo ' 'were well-tolerated, though liver transaminase elevations were more common in the Lambda vs. ' 'placebo arm (15/60 vs 5/60; p = 0.027). In this study, a single dose of subcutaneous ' 'Peginterferon Lambda-1a neither shortened the duration of SARS-CoV-2 viral shedding nor ' 'improved symptoms in outpatients with uncomplicated COVID-19.</jats:p>', 'DOI': '10.1038/s41467-021-22177-1', 'type': 'journal-article', 'created': {'date-parts': [[2021, 3, 30]], 'date-time': '2021-03-30T10:03:17Z', 'timestamp': 1617098597000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 38, 'title': [ 'Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized ' 'placebo-controlled trial'], 'prefix': '10.1038', 'volume': '12', 'author': [ { 'ORCID': 'http://orcid.org/0000-0001-6305-758X', 'authenticated-orcid': False, 'given': 'Prasanna', 'family': 'Jagannathan', 'sequence': 'first', 'affiliation': []}, {'given': 'Jason R.', 'family': 'Andrews', 'sequence': 'additional', 'affiliation': []}, {'given': 'Hector', 'family': 'Bonilla', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-0757-7959', 'authenticated-orcid': False, 'given': 'Haley', 'family': 'Hedlin', 'sequence': 'additional', 'affiliation': []}, {'given': 'Karen B.', 'family': 'Jacobson', 'sequence': 'additional', 'affiliation': []}, {'given': 'Vidhya', 'family': 'Balasubramanian', 'sequence': 'additional', 'affiliation': []}, {'given': 'Natasha', 'family': 'Purington', 'sequence': 'additional', 'affiliation': []}, {'given': 'Savita', 'family': 'Kamble', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-4667-5973', 'authenticated-orcid': False, 'given': 'Christiaan R.', 'family': 'de Vries', 'sequence': 'additional', 'affiliation': []}, {'given': 'Orlando', 'family': 'Quintero', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-7949-9531', 'authenticated-orcid': False, 'given': 'Kent', 'family': 'Feng', 'sequence': 'additional', 'affiliation': []}, {'given': 'Catherine', 'family': 'Ley', 'sequence': 'additional', 'affiliation': []}, {'given': 'Dean', 'family': 'Winslow', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jennifer', 'family': 'Newberry', 'sequence': 'additional', 'affiliation': []}, {'given': 'Karlie', 'family': 'Edwards', 'sequence': 'additional', 'affiliation': []}, {'given': 'Colin', 'family': 'Hislop', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ingrid', 'family': 'Choong', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yvonne', 'family': 'Maldonado', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jeffrey', 'family': 'Glenn', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-8099-2975', 'authenticated-orcid': False, 'given': 'Ami', 'family': 'Bhatt', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-6946-7627', 'authenticated-orcid': False, 'given': 'Catherine', 'family': 'Blish', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-3894-685X', 'authenticated-orcid': False, 'given': 'Taia', 'family': 'Wang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Chaitan', 'family': 'Khosla', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-8751-4810', 'authenticated-orcid': False, 'given': 'Benjamin A.', 'family': 'Pinsky', 'sequence': 'additional', 'affiliation': []}, {'given': 'Manisha', 'family': 'Desai', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-7342-5366', 'authenticated-orcid': False, 'given': 'Julie', 'family': 'Parsonnet', 'sequence': 'additional', 'affiliation': []}, {'given': 'Upinder', 'family': 'Singh', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2021, 3, 30]]}, 'reference': [ { 'key': '22177_CR1', 'unstructured': 'COVID-19 Dashboard by the Center for Systems Science and Engineering ' '(CSSE) at Johns Hopkins University (JHU) (Johns Hopkins University, ' '2021). https://coronavirus.jhu.edu/map.html.'}, { 'key': '22177_CR2', 'doi-asserted-by': 'publisher', 'first-page': '773', 'DOI': '10.1016/S1473-3099(20)30195-X', 'volume': '20', 'author': 'D Baud', 'year': '2020', 'unstructured': 'Baud, D. et al. Real estimates of mortality following COVID-19 ' 'infection. Lancet Infect. Dis. 20, 773 (2020).', 'journal-title': 'Lancet Infect. Dis.'}, { 'key': '22177_CR3', 'doi-asserted-by': 'publisher', 'first-page': '870', 'DOI': '10.1016/j.chom.2020.05.008', 'volume': '27', 'author': 'A Park', 'year': '2020', 'unstructured': 'Park, A. & Iwasaki, A. Type I and Type III interferons—induction, ' 'signaling, evasion, and application to combat COVID-19. Cell Host ' 'Microbe 27, 870–878 (2020).', 'journal-title': 'Cell Host Microbe'}, { 'key': '22177_CR4', 'doi-asserted-by': 'publisher', 'first-page': '583', 'DOI': '10.1016/j.coi.2011.07.007', 'volume': '23', 'author': 'SV Kotenko', 'year': '2011', 'unstructured': 'Kotenko, S. V. IFN-lambdas. Curr. Opin. Immunol. 23, 583–590 (2011).', 'journal-title': 'Curr. Opin. Immunol.'}, { 'key': '22177_CR5', 'doi-asserted-by': 'publisher', 'first-page': '7749', 'DOI': '10.1128/JVI.02438-06', 'volume': '81', 'author': 'Z Zhou', 'year': '2007', 'unstructured': 'Zhou, Z. et al. Type III interferon (IFN) induces a type I IFN-like ' 'response in a restricted subset of cells through signaling pathways ' 'involving both the Jak-STAT pathway and the mitogen-activated protein ' 'kinases. J. Virol. 81, 7749–7758 (2007).', 'journal-title': 'J. Virol.'}, { 'key': '22177_CR6', 'doi-asserted-by': 'publisher', 'first-page': '907', 'DOI': '10.1016/j.immuni.2019.03.025', 'volume': '50', 'author': 'HM Lazear', 'year': '2019', 'unstructured': 'Lazear, H. M., Schoggins, J. W. & Diamond, M. S. Shared and distinct ' 'functions of Type I and Type III interferons. Immunity 50, 907–923 ' '(2019).', 'journal-title': 'Immunity'}, { 'key': '22177_CR7', 'doi-asserted-by': 'publisher', 'first-page': '1418', 'DOI': '10.1080/22221751.2020.1780953', 'volume': '9', 'author': 'CK Yuen', 'year': '2020', 'unstructured': 'Yuen, C. K. et al. SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as ' 'potent interferon antagonists. Emerg. Microbes Infect. 9, 1418–1428 ' '(2020).', 'journal-title': 'Emerg. Microbes Infect.'}, { 'key': '22177_CR8', 'doi-asserted-by': 'publisher', 'first-page': '1400', 'DOI': '10.1093/cid/ciaa410', 'volume': '71', 'author': 'H Chu', 'year': '2020', 'unstructured': 'Chu, H. et al. Comparative replication and immune activation profiles of ' 'SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with ' 'implications for the pathogenesis of COVID-19. Clin. Infect. Dis. 71, ' '1400–1409 (2020).', 'journal-title': 'Clin. Infect. Dis.'}, { 'key': '22177_CR9', 'doi-asserted-by': 'publisher', 'first-page': '1210', 'DOI': '10.1126/science.abc6261', 'volume': '369', 'author': 'PS Arunachalam', 'year': '2020', 'unstructured': 'Arunachalam, P. S. et al. Systems biological assessment of immunity to ' 'mild versus severe COVID-19 infection in humans. Science 369, 1210–1220 ' '(2020).', 'journal-title': 'Science'}, { 'key': '22177_CR10', 'doi-asserted-by': 'publisher', 'first-page': '718', 'DOI': '10.1126/science.abc6027', 'volume': '369', 'author': 'J Hadjadj', 'year': '2020', 'unstructured': 'Hadjadj, J. et al. Impaired type I interferon activity and inflammatory ' 'responses in severe COVID-19 patients. Science 369, 718–724 (2020).', 'journal-title': 'Science'}, { 'key': '22177_CR11', 'doi-asserted-by': 'publisher', 'first-page': '13958', 'DOI': '10.1074/jbc.AC120.013788', 'volume': '295', 'author': 'U Felgenhauer', 'year': '2020', 'unstructured': 'Felgenhauer, U. et al. Inhibition of SARS-CoV-2 by type I and type III ' 'interferons. J. Biol. Chem. 295, 13958–13964 (2020).', 'journal-title': 'J. Biol. Chem.'}, { 'key': '22177_CR12', 'doi-asserted-by': 'publisher', 'first-page': '560', 'DOI': '10.1038/s41586-020-2708-8', 'volume': '586', 'author': 'KH Dinnon', 'year': '2020', 'unstructured': 'Dinnon, K. H. et al. A mouse-adapted model of SARS-CoV-2 to test ' 'COVID-19 countermeasures. Nature 586, 560–566 (2020).', 'journal-title': 'Nature'}, { 'key': '22177_CR13', 'doi-asserted-by': 'publisher', 'first-page': '1061', 'DOI': '10.3389/fimmu.2020.01061', 'volume': '11', 'author': 'Q Zhou', 'year': '2020', 'unstructured': 'Zhou, Q. et al. Interferon-alpha2b treatment for COVID-19. Front. ' 'Immunol. 11, 1061 (2020).', 'journal-title': 'Front. Immunol.'}, { 'key': '22177_CR14', 'doi-asserted-by': 'publisher', 'first-page': '1695', 'DOI': '10.1016/S0140-6736(20)31042-4', 'volume': '395', 'author': 'IF Hung', 'year': '2020', 'unstructured': 'Hung, I. F. et al. Triple combination of interferon beta-1b, ' 'lopinavir-ritonavir, and ribavirin in the treatment of patients admitted ' 'to hospital with COVID-19: an open-label, randomised, phase 2 trial. ' 'Lancet 395, 1695–1704 (2020).', 'journal-title': 'Lancet'}, { 'key': '22177_CR15', 'doi-asserted-by': 'publisher', 'first-page': '196', 'DOI': '10.1016/S2213-2600(20)30511-7', 'volume': '9', 'author': 'PD Monk', 'year': '2021', 'unstructured': 'Monk, P. D. et al. Safety and efficacy of inhaled nebulised interferon ' 'beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, ' 'double-blind, placebo-controlled, phase 2 trial. Lancet Respir. Med. 9, ' '196–206 (2021).', 'journal-title': 'Lancet Respir. Med.'}, { 'key': '22177_CR16', 'doi-asserted-by': 'publisher', 'first-page': '106688', 'DOI': '10.1016/j.intimp.2020.106688', 'volume': '85', 'author': 'F Dastan', 'year': '2020', 'unstructured': 'Dastan, F. et al. Subcutaneous administration of interferon beta-1a for ' 'COVID-19: a non-controlled prospective trial. Int. Immunopharmacol. 85, ' '106688 (2020).', 'journal-title': 'Int. Immunopharmacol.'}, { 'key': '22177_CR17', 'doi-asserted-by': 'publisher', 'first-page': 'e01061', 'DOI': '10.1128/AAC.01061-20', 'volume': '64', 'author': 'E Davoudi-Monfared', 'year': '2020', 'unstructured': 'Davoudi-Monfared, E. et al. A Randomized Clinical Trial of the efficacy ' 'and safety of interferon beta-1a in treatment of severe COVID-19. ' 'Antimicrob. Agents Chemother. 64, e01061 (2020).', 'journal-title': 'Antimicrob. Agents Chemother.'}, { 'key': '22177_CR18', 'doi-asserted-by': 'publisher', 'first-page': '5670', 'DOI': '10.1128/JVI.00272-10', 'volume': '84', 'author': 'M Mordstein', 'year': '2010', 'unstructured': 'Mordstein, M. et al. Lambda interferon renders epithelial cells of the ' 'respiratory and gastrointestinal tracts resistant to viral infections. ' 'J. Virol. 84, 5670–5677 (2010).', 'journal-title': 'J. Virol.'}, { 'key': '22177_CR19', 'doi-asserted-by': 'publisher', 'first-page': 'e1000017', 'DOI': '10.1371/journal.ppat.1000017', 'volume': '4', 'author': 'C Sommereyns', 'year': '2008', 'unstructured': 'Sommereyns, C., Paul, S., Staeheli, P. & Michiels, T. IFN-lambda ' '(IFN-lambda) is expressed in a tissue-dependent fashion and primarily ' 'acts on epithelial cells in vivo. PLoS Pathog. 4, e1000017 (2008).', 'journal-title': 'PLoS Pathog.'}, { 'key': '22177_CR20', 'doi-asserted-by': 'publisher', 'first-page': '197', 'DOI': '10.1016/j.virol.2010.02.022', 'volume': '401', 'author': 'NE Pagliaccetti', 'year': '2010', 'unstructured': 'Pagliaccetti, N. E., Chu, E. N., Bolen, C. R., Kleinstein, S. H. & ' 'Robek, M. D. Lambda and alpha interferons inhibit hepatitis B virus ' 'replication through a common molecular mechanism but with different in ' 'vivo activities. Virology 401, 197–206 (2010).', 'journal-title': 'Virology'}, { 'key': '22177_CR21', 'doi-asserted-by': 'publisher', 'first-page': '3851', 'DOI': '10.1128/JVI.79.6.3851-3854.2005', 'volume': '79', 'author': 'MD Robek', 'year': '2005', 'unstructured': 'Robek, M. D., Boyd, B. S. & Chisari, F. V. Lambda interferon inhibits ' 'hepatitis B and C virus replication. J. Virol. 79, 3851–3854 (2005).', 'journal-title': 'J. Virol.'}, { 'key': '22177_CR22', 'doi-asserted-by': 'publisher', 'first-page': '1099', 'DOI': '10.15252/emmm.201606413', 'volume': '8', 'author': 'S Davidson', 'year': '2016', 'unstructured': 'Davidson, S. et al. IFNlambda is a potent anti-influenza therapeutic ' 'without the inflammatory side effects of IFNalpha treatment. EMBO Mol. ' 'Med. 8, 1099–1112 (2016).', 'journal-title': 'EMBO Mol. Med.'}, { 'key': '22177_CR23', 'doi-asserted-by': 'publisher', 'first-page': '1238', 'DOI': '10.1016/j.jhep.2014.07.022', 'volume': '61', 'author': 'AJ Muir', 'year': '2014', 'unstructured': 'Muir, A. J. et al. A randomized phase 2b study of peginterferon ' 'lambda-1a for the treatment of chronic HCV infection. J. Hepatol. 61, ' '1238–1246 (2014).', 'journal-title': 'J. Hepatol.'}, { 'key': '22177_CR24', 'doi-asserted-by': 'publisher', 'first-page': '1410', 'DOI': '10.1093/cid/ciaa453', 'volume': '71', 'author': "TR O'Brien", 'year': '2020', 'unstructured': "O'Brien, T. R. et al. Weak induction of interferon expression by severe " 'acute respiratory syndrome Coronavirus 2 Supports Clinical Trials of ' 'Interferon-lambda to treat early Coronavirus Disease 2019. Clin. Infect. ' 'Dis. 71, 1410–1412 (2020).', 'journal-title': 'Clin. Infect. Dis.'}, { 'key': '22177_CR25', 'doi-asserted-by': 'publisher', 'first-page': 'e20200653', 'DOI': '10.1084/jem.20200653', 'volume': '217', 'author': 'L Prokunina-Olsson', 'year': '2020', 'unstructured': 'Prokunina-Olsson, L. et al. COVID-19 and emerging viral infections: the ' 'case for interferon lambda. J. Exp. Med. 217, e20200653 (2020).', 'journal-title': 'J. Exp. Med.'}, { 'key': '22177_CR26', 'unstructured': 'Centers for Disease Control and Prevention. CDC 2019-nCoV Real-Time ' 'RT-PCR Diagnostic Panel instructions for use (effective February 4, ' '2020). ' 'https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html.'}, { 'key': '22177_CR27', 'doi-asserted-by': 'publisher', 'first-page': '67', 'DOI': '10.1038/s41590-020-00828-7', 'volume': '22', 'author': 'S Chakraborty', 'year': '2020', 'unstructured': 'Chakraborty, S. et al. Proinflammatory IgG Fc structures in patients ' 'with severe COVID-19. Nat. Immunol. 22, 67–73 (2020).', 'journal-title': 'Nat. Immunol.'}, { 'key': '22177_CR28', 'doi-asserted-by': 'publisher', 'first-page': '1011', 'DOI': '10.1016/j.jhep.2015.12.018', 'volume': '64', 'author': 'HLY Chan', 'year': '2016', 'unstructured': 'Chan, H. L. Y. et al. Peginterferon lambda for the treatment of ' 'HBeAg-positive chronic hepatitis B: A randomized phase 2b study ' '(LIRA-B). J. Hepatol. 64, 1011–1019 (2016).', 'journal-title': 'J. Hepatol.'}, { 'key': '22177_CR29', 'unstructured': 'Eiger_BioPharmaceuticals. Investigators Brochure version 3 11, May 2018 ' '(Eiger_BioPharmaceuticals, 2018).'}, { 'key': '22177_CR30', 'doi-asserted-by': 'publisher', 'first-page': '27', 'DOI': '10.4103/0976-0105.177703', 'volume': '7', 'author': 'AB Nair', 'year': '2016', 'unstructured': 'Nair, A. B. & Jacob, S. A simple practice guide for dose conversion ' 'between animals and human. J. Basic Clin. Pharm. 7, 27–31 (2016).', 'journal-title': 'J. Basic Clin. Pharm.'}, { 'key': '22177_CR31', 'doi-asserted-by': 'publisher', 'first-page': '712', 'DOI': '10.1126/science.abc2061', 'volume': '369', 'author': 'J Major', 'year': '2020', 'unstructured': 'Major, J. et al. Type I and III interferons disrupt lung epithelial ' 'repair during recovery from viral infection. Science 369, 712–717 ' '(2020).', 'journal-title': 'Science'}, { 'key': '22177_CR32', 'doi-asserted-by': 'publisher', 'first-page': '706', 'DOI': '10.1126/science.abc3545', 'volume': '369', 'author': 'A Broggi', 'year': '2020', 'unstructured': 'Broggi, A. et al. Type III interferons disrupt the lung epithelial ' 'barrier upon viral recognition. Science 369, 706–712 (2020).', 'journal-title': 'Science'}, { 'key': '22177_CR33', 'doi-asserted-by': 'publisher', 'first-page': 'e1004556', 'DOI': '10.1371/journal.ppat.1004556', 'volume': '10', 'author': 'A Egli', 'year': '2014', 'unstructured': 'Egli, A. et al. IL-28B is a key regulator of B- and T-cell vaccine ' 'responses against influenza. PLoS Pathog. 10, e1004556 (2014).', 'journal-title': 'PLoS Pathog.'}, { 'key': '22177_CR34', 'unstructured': 'Feld, J. J. et al. Peginterferon-lambda for the treatment of COVID-19 in ' 'outpatients. medRxiv, 2020.2011.2009.20228098 (2020).'}, { 'key': '22177_CR35', 'doi-asserted-by': 'publisher', 'first-page': 'eabd4570', 'DOI': '10.1126/science.abd4570', 'volume': '370', 'author': 'Q Zhang', 'year': '2020', 'unstructured': 'Zhang, Q. et al. Inborn errors of type I IFN immunity in patients with ' 'life-threatening COVID-19. Science 370, eabd4570 (2020).', 'journal-title': 'Science'}, { 'key': '22177_CR36', 'doi-asserted-by': 'publisher', 'first-page': 'eabd4585', 'DOI': '10.1126/science.abd4585', 'volume': '370', 'author': 'P Bastard', 'year': '2020', 'unstructured': 'Bastard, P. et al. Autoantibodies against type I IFNs in patients with ' 'life-threatening COVID-19. Science 370, eabd4585 (2020).', 'journal-title': 'Science'}, { 'key': '22177_CR37', 'unstructured': 'Center, C.o.S.C.E.O. Santa Clara County COVID-19 Demographics Dashboard, ' 'Vol. 2020 (Center, C.o.S.C.E.O).'}, { 'key': '22177_CR38', 'doi-asserted-by': 'publisher', 'first-page': '2534', 'DOI': '10.1056/NEJMsa2011686', 'volume': '382', 'author': 'EG Price-Haywood', 'year': '2020', 'unstructured': 'Price-Haywood, E. G., Burton, J., Fort, D. & Seoane, L. Hospitalization ' 'and mortality among Black patients and White patients with Covid-19. N. ' 'Engl. J. Med. 382, 2534–2543 (2020).', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '22177_CR39', 'doi-asserted-by': 'publisher', 'first-page': '759', 'DOI': '10.15585/mmwr.mm6924e2', 'volume': '69', 'author': 'EK Stokes', 'year': '2020', 'unstructured': 'Stokes, E. K. et al. Coronavirus Disease 2019 Case Surveillance— United ' 'States, January 22–May 30, 2020. Morb. Mortal. Wkly Rep. 69, 759–765 ' '(2020).', 'journal-title': 'Morb. Mortal. Wkly Rep.'}, { 'key': '22177_CR40', 'doi-asserted-by': 'publisher', 'first-page': 'e59', 'DOI': '10.1056/NEJMp2021971', 'volume': '383', 'author': 'DB Chastain', 'year': '2020', 'unstructured': 'Chastain, D. B. et al. Racial disproportionality in Covid Clinical ' 'Trials. N. Engl. J. Med. 383, e59 (2020).', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '22177_CR41', 'doi-asserted-by': 'publisher', 'first-page': '201', 'DOI': '10.1056/NEJMp2012910', 'volume': '383', 'author': 'M Chowkwanyun', 'year': '2020', 'unstructured': 'Chowkwanyun, M. & Reed, A. L. Jr. Racial health disparities and ' 'Covid-19—caution and context. N. Engl. J. Med 383, 201–203 (2020).', 'journal-title': 'N. Engl. J. Med'}, { 'key': '22177_CR42', 'doi-asserted-by': 'publisher', 'first-page': '238', 'DOI': '10.1056/NEJMoa2035002', 'volume': '384', 'author': 'DM Weinreich', 'year': '2020', 'unstructured': 'Weinreich, D. M. et al. REGN-COV2, a neutralizing antibody cocktail, in ' 'outpatients with Covid-19. N. Engl. J. Med. 384, 238–251 (2020).', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '22177_CR43', 'doi-asserted-by': 'publisher', 'unstructured': 'Bullard, J. et al. Predicting infectious SARS-CoV-2 from diagnostic ' 'samples. Clin. Infect. Dis. ciaa638 https://doi.org/10.1093/cid/ciaa638 ' '(2020). Epub ahead of print.', 'DOI': '10.1093/cid/ciaa638'}, { 'key': '22177_CR44', 'doi-asserted-by': 'publisher', 'first-page': '2001483', 'DOI': '10.2807/1560-7917.ES.2020.25.32.2001483', 'volume': '25', 'author': 'A Singanayagam', 'year': '2020', 'unstructured': 'Singanayagam, A. et al. Duration of infectiousness and correlation with ' 'RT-PCR cycle threshold values in cases of COVID-19, England, January to ' 'May 2020. Eur. Surveill. 25, 2001483 (2020).', 'journal-title': 'Eur. Surveill.'}, { 'key': '22177_CR45', 'doi-asserted-by': 'publisher', 'first-page': '1967', 'DOI': '10.1001/jama.2020.5445', 'volume': '323', 'author': 'CA Hogan', 'year': '2020', 'unstructured': 'Hogan, C. A., Sahoo, M. K. & Pinsky, B. A. Sample pooling as a strategy ' 'to detect community transmission of SARS-CoV-2. JAMA 323, 1967–1969 ' '(2020).', 'journal-title': 'JAMA'}, { 'key': '22177_CR46', 'doi-asserted-by': 'publisher', 'first-page': '104383', 'DOI': '10.1016/j.jcv.2020.104383', 'volume': '127', 'author': 'CA Hogan', 'year': '2020', 'unstructured': 'Hogan, C. A. et al. Comparison of the Panther Fusion and a ' 'laboratory-developed test targeting the envelope gene for detection of ' 'SARS-CoV-2. J. Clin. Virol. 127, 104383 (2020).', 'journal-title': 'J. Clin. Virol.'}, { 'key': '22177_CR47', 'first-page': '2000045', 'volume': '25', 'author': 'VM Corman', 'year': '2020', 'unstructured': 'Corman, V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by ' 'real-time RT-PCR. Eur. Surveill. 25, 2000045 (2020).', 'journal-title': 'Eur. Surveill.'}, { 'key': '22177_CR48', 'unstructured': 'Team, R.C. R: A Language and Environment for Statistical Computing (R ' 'Foundation for Statistical Computing, 2019).'}], 'container-title': ['Nature Communications'], 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'http://www.nature.com/articles/s41467-021-22177-1.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'http://www.nature.com/articles/s41467-021-22177-1', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'http://www.nature.com/articles/s41467-021-22177-1.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 12, 2]], 'date-time': '2021-12-02T07:22:26Z', 'timestamp': 1638429746000}, 'score': 1, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 3, 30]]}, 'references-count': 48, 'journal-issue': {'issue': '1', 'published-print': {'date-parts': [[2021, 12]]}}, 'alternative-id': ['22177'], 'URL': 'http://dx.doi.org/10.1038/s41467-021-22177-1', 'relation': {}, 'ISSN': ['2041-1723'], 'issn-type': [{'value': '2041-1723', 'type': 'electronic'}], 'subject': [ 'General Physics and Astronomy', 'General Biochemistry, Genetics and Molecular Biology', 'General Chemistry'], 'published': {'date-parts': [[2021, 3, 30]]}, 'assertion': [ { 'value': '22 December 2020', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '3 March 2021', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '30 March 2021', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': 'C.H. and I.C. are scientists at Eiger BioPharmaceuticals, Inc., which provided ' 'the Interferon Lambda used for this study. J.G. serves on the board of Eiger ' 'BioPharmaceuticals, Inc. C.H. and I.C. own stock and options of Eiger ' 'BioPharmaceuticals, Inc. J.G. has an equity interest in Eiger ' 'BioPharmaceuticals, Inc. J.G. and I.C. are inventors on a pending patent ' 'application relating to the use of interferon lambda for coronavirus. Eiger ' 'BioPharmaceuticals played no role in study design, conduct of the study, or ' 'analysis of the data. All other authors declare no competing interests.', 'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Competing interests'}}], 'article-number': '1967'}